Online data supplement
|
|
- Pierce Warner
- 5 years ago
- Views:
Transcription
1 Online data supplement Title: Fluoroquinolone therapy for the prevention of multi-drug resistant tuberculosis in contacts: a cost-effectiveness analysis Authors: Gregory J Fox Olivia Oxlade Dick Menzies E1
2 Supplementary Methods Costs and Utilities The additional cost and the number of additional cases of MDR-TB prevented using the FPT strategy relative to the no treatment strategy was calculated. The outcomes (including costs) were expressed as events (or costs) per 1,000 treated contacts. QALY calculations were based upon weights for disease states were derived studies in relevant populations (E1), shown in Table 1 in the main text. The utility weight for contacts taking FPT therapy was expected to be equivalent to subjects in the no treatment group, consistent with findings among matched contacts of patients with DS-TB treated taking isoniazid preventative therapy (E2). Where relevant, a strategy was considered cost-effective if the incremental cost effectiveness ratio (ICER) was less than the willingness to pay threshold of $50,000 per QALY (E3). Strategies were considered dominant if the expected cost was lower and outcomes were also improved, in which case an ICER was not given. Adverse drug reactions Data from recent randomized controlled trials have demonstrated that long term FQN therapy is safe and well tolerated in treatment of active disease (E4, E5). Consequently, subjects receiving FQN treatment were considered to have a very low risk of developing a severe adverse event (1%) (E6), with a drug related death rate of < 0.01% overall. If subjects developed a severe adverse event, the drug was assumed to be discontinued and therefore ineffective. E2
3 Direct treatment and surveillance costs Direct treatment costs were calculated in $2014 US. Treatment costs were derived from Marks et al (E7) and the 2014 American Hospital Formulary Service Drug information 2014 (E8), adjusted for inflation (8.9% between 2010 and 2014) (9). Costs of six months of FQN The costs of six months of FQN therapy included baseline complete blood count and liver function tests ($ $11.70)*( ), six clinic visits ($38.63 * ( ) * 6) (E7), and the cost of six months of generic levofloxacin ($69.97 for 60 tablets * 3 = $209.91) (E8), a total of $487 per person. Costs of routine surveillance The cost of routine surveillance (no preventive therapy) for those not receiving FQN therapy included four clinic visits over a two-year period ($38.63 * ( ) * 4) and four plain chest radiographs ($30.97 * ( ) * 4), a total cost in $2014 US of $303 per person. Costs of MDR-TB treatment The cost of treatment for MDR-TB were primarily derived from the 2010 treatment costs of Marks et al (E7). The cost of 20 months of 750mg daily brand name levofloxacin, at the drug prices reported by Marks et al ($ per mg, a total of $16,183.93) was deducted from the average cost of treatment ($134,000), and the cost of generic levofloxacin for the same duration was added ($643 in $2010 US) then adjusted for inflation, giving a total treatment cost in $2014 US of $118,459 * ( ), that is $129,001. E3
4 Costs of QMDR-TB treatment The treatment cost of QMDR-TB was derived similarly. The cost of 26 months of 750mg daily brand name levofloxacin, at the drug prices cited by Marks et al ($ per mg, a total of $21,039) (E7) was deducted from the average cost of treatment ($430,000), and the cost of generic levofloxacin given for the same duration was added ($835 in $2010 US) then adjusted for inflation, giving a total treatment cost of $409,796 * ( ), that is $446,268 in $2014 US. Costs of DS-TB treatment The cost of treatment for DS-TB was $17,000 * ( ) (E7), that is $18,513 in $2014 US. Costs of treating severe adverse events The cost of treating severe adverse events was for 7 days of inpatient care at the average rate adjusted for inflation: (7 * $1419) * ( ), a total of $10,817 in $2014 US. E4
5 Supplementary text references E1. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, MH E. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009;169: E2. Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, Menzies D, Vadeboncoeur C, Vissandjee B, Wynne A, Schwartzman K. The impact of tuberculosis on health utility: a longitudinal cohort study. Qual Life Res E3. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3): E4. Gillespie SH, Crook A, Mchugh T, Mendel C, Meredith S, Murray S, Pappas F, Phillips P, Nunn A, Consortium ftr. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med E5. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C, Project OGfT. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17): E6. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug safety 2010;33(5): E7. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K, Consortium TBES. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, Emerg Infect Dis. 2014;20(5): E5
6 E8. American Society of Health System Pharmacists. American Hospital Formulary Service Drug Information McEvoy G, editor. E6
7 Supplementary Table E1: Incidence of QMDR-TB among infected contacts according to the effectiveness of FPT Incidence of QMDR-TB per 1,000 contacts Effectiveness of FPT No FPT given FPT given Reduction in QMDR- TB with FPT (%) Absolute difference a (% change b ) 10% % 20% % 30% % 40% % 50% % 60% % 70% % 80% % 90% % a Some values may differ slightly on account of rounding. b Percentage reduction under FPT relative to no FPT. Negative values indicate a lower incidence of QMDR- TB under the FPT scenario. FPT = fluoroquinolone preventive therapy. All costs are given in $2014 US. Analyses assuming 60% effectiveness of fluoroquinolone preventive therapy (the base case) are indicated in bold. E7
8 Supplementary Table E2: Sensitivity analysis varying the rate of acquired fluoroquinolone resistance upon the incidence of fluoroquinolone resistant multi-drug resistant disease among infected contacts Incidence of QMDR-TB per 1,000 contacts Proportion of infected contacts taking FPT developing acquired FQN resistance Cases of incident QMDR-TB No FPT Reduction in cases of QMDR-TB with FPT Absolute (%) given FPT given difference (% change b ) 0% % Base case a 1% % 2% % 3% % 4% % 5% % 6% % 7% % 8% % 9% % 10% % a In the base case, used in the main analyses, 1% of contacts treated with FPT acquired additional fluoroquinolone resistance while taking preventive therapy. b Negative values represent cases of QMDR-TB prevented, and positive values represent additional cases of QMDR-TB in the FPT group, compared to the no FPT group. QMDR-TB = multi-drug resistant tuberculosis with additional fluoroquinolone resistance. FQN = fluoroquinolone. FPT = Fluoroquinolone preventive therapy. E8
9 Supplementary Table E3: Projected health system costs of FPT for 6, 9 and 12 months, per 1000 infected household contacts of individuals with MDR-TB Cost according to duration of FPT 6 months 9 months 12 months (baseline case) Health system costs of $487,000 $718,000 $950,000 delivering 6FQN to 1,000 contacts Total health system costs per 1,000 contacts Total cost of no FPT $10,555,343 $10,555,343 $10,555,343 Total cost of FPT $5,292,534 $5,521,343 $5,750,997 Cost difference with FPT * -$5,262,810 -$5,033,484 -$4,804,347 All costs given in 2014 $US. FPT = fluoroquinolone preventive therapy. MDR-TB = multidrug resistant tuberculosis. 6FQN = six months of fluroquinolone, including the purchase of levofloxacin, baseline blood tests and monthly clinic visits for those taking preventive therapy for either 6 months, 9 months or 12 months. * Negative cost difference represents a saving with FPT. E9
10 Supplementary Figure E1: Tornado diagram showing one-way sensitivity analyses showing incremental health system costs of fluoroquinolone preventive therapy EV = -$5,263 Incremental cost of FPT per contact in dollars ($US 2014) This one-way sensitivity analysis shows the incremental costs comparing FPT with no FPT. The vertical line represents the expected incremental cost when the base case of all parameters is used. Negative values represent a reduction in cost in the FPT group. Values are for each contact, and so to obtain values for 1,000 contacts these are multiplied by 1,000. Not all parameters are included only those responsible for the greatest variation are shown. MDR-TB = Multidrug resistant tuberculosis. FPT = fluoroquinolone preventive therapy. EV = expected value. TB = tuberculosis. FQ = fluoroquinolone. AE = adverse events. 6FQ = six months of fluoroquinolone preventive therapy. QMDR-TB = Quinolone Resistant Multidrug resistant TB. E10
11 Supplementary Figure E2: One-way sensitivity analysis of the incremental incidence of MDR-TB, comparing FPT versus no preventive therapy Incremental incidence of MDR-TB (cases of MDR-TB per contact per year) This one-way sensitivity analysis shows the incremental incidence of MDR-TB, comparing FPT with no FPT. The vertical line represents the incremental effects when the base case estimates of all parameters are used. Negative numbers represent a reduction in incidence in the FPT group. Values are for each contact, and so to obtain values for 1,000 contacts these are multiplied by 1,000. Not all parameters are shown, with those responsible for the greatest variation shown. MDR-TB = Multidrug resistant tuberculosis. FPT = fluoroquinolone preventive therapy. EV = expected value (FPT versus no FPT). TB = tuberculosis. FQ = fluoroquinolone. AE = adverse events. 6FQ = six months of fluoroquinolone preventive therapy. QMDR = Quinolone Resistant Multidrug resistant TB. E11
12 Difference in health system costs of preventive therapy per contact compared to no preventive therapy ($2014 US / contact) FPT cost saving Equivalent cost Supplementary Figure E3: Scatter plot showing the health system costs and incidence of MDR-TB among those taking preventive therapy compared with those with no preventive therapy, using probabilistic sensitivity analysis - FPT more effective Difference in the proportion of contacts developing incident MDR-TB with FPT compared to no FPT Equivalent effectiveness The ellipse indicates the 95% Uncertainty Range. The outcomes of 1,000 trials are shown. All points on the graph below the horizontal dashed line, and to the left of the vertical dashed line, are considered cost saving and effective (i.e. dominant), as they represent cost savings and reduced incident MDR-TB with the FPT scenario. FPT = Fluoroquinolone preventive therapy E12
Clinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationIDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital
Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital Organization Name: St. Joseph Medical Center Type: Acute Care Hospital Contact Person: Leigh Chapman RN,
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationTB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationTHE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationTB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationORIGINAL INVESTIGATION. Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease
ORIGINAL INVESTIGATION Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease Pinky D. Gaba, MD; Connie Haley, MD, MPH; Marie R. Griffin, MD,
More informationCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.80.2.143 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2017;80:143-152 Current Status of Fluoroquinolone Use for Treatment of Tuberculosis
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationBugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care
Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care Molly Curran, PharmD, BCPS Clinical Assistant Professor The University of Texas College of Pharmacy Clinical
More informationAntibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee
Antibiotic Stewardship at MetroWest Medical Center Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship Committee Subcommittee of Pharmacy and Therapeutics. Also
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationIntroduction of Bedaquiline in the Philippines
Introduction of Bedaquiline in the Philippines 24th PhilCAT Annual Convention Crown Plaza Hotel August 18,2107 Vivian S. Lofranco, MD., PHSAE National Clinical Coordinator, BDQ MDR-TB is highly contagious
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationDrug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationAntimicrobial Stewardship Strategy: Intravenous to oral conversion
Antimicrobial Stewardship Strategy: Intravenous to oral conversion Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated. Description This is an
More informationSt. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report
St. Joseph s General Hospital Vegreville and Mary Immaculate Care Centre Antimicrobial Stewardship Report January to June 217 Introduction Antibiotics are among the most commonly prescribed medications
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationCephalosporins, Quinolones and Co-amoxiclav Prescribing Audit
Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationSupplementary Fig. 1: Comparison of chase parameters for focal pack (a-f, n=1119) and for 4 dogs from 3 other packs (g-m, n=107).
Supplementary Fig. 1: Comparison of chase parameters for focal pack (a-f, n=1119) and for 4 dogs from 3 other packs (g-m, n=107). (a,g) Maximum stride speed, (b,h) maximum tangential acceleration, (c,i)
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationTitle: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes
ERJ Express. Published on October 25, 2012 as doi: 10.1183/09031936.00134712 Title: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes Authors: D. Falzon, N. Gandhi,
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationDevelopment of the New Zealand strategy for local eradication of tuberculosis from wildlife and livestock
Livingstone et al. New Zealand Veterinary Journal http://dx.doi.org/*** S1 Development of the New Zealand strategy for local eradication of tuberculosis from wildlife and livestock PG Livingstone* 1, N
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationStudy of Fluoroquinolone Usage Sensitivity and Resistance Patterns
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2013, 5 (5):195-199 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationPresenter: Marc Meyer, BPharm, RPh, CIC, FAPIC Clinical Pharmacists, Infection Preventionist, Antibiotic Stewardship Pharmacist Southwest Health
Presenter: Marc Meyer, BPharm, RPh, CIC, FAPIC Clinical Pharmacists, Infection Preventionist, Antibiotic Stewardship Pharmacist Southwest Health System, Cortez, Colorado None How do AU vendors and NHSN
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationCritically Appraised Topics in the Radiodiagnosis Curriculum
Critically Appraised Topics in the Radiodiagnosis Curriculum What is a Critically Appraised Topic? There are different ways to interpret the term Critically Appraised Topic. Within the RANZCR Radiodiagnosis
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationAntibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review
Clinical Review & Education Review Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review Jonathan S. Lee, MD; Daniel L. Giesler, MD, PharmD; Walid F. Gellad,
More informationAntimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali,
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/88030.htm Antimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali, Rwanda. Ashok
More informationAssessment of empirical antibiotic therapy in a tertiary-care hospital: An observational descriptive study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 9 Ver. VI (September). 2016), PP 118-124 www.iosrjournals.org Assessment of empirical antibiotic
More informationAntibiotic courses and antibiotic conservation, getting the balance right
Antibiotic courses and antibiotic conservation, getting the balance right Prof Martin Llewelyn Brighton and Sussex Medical School Brighton and Sussex University Hospitals NHS Trust The King's Fund: Ideas
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationHiking Shoes OR, HOW EQUIPMENT MATTERS
Hiking Shoes OR, HOW EQUIPMENT MATTERS Beyond the Leash EQUIPMENT MAKES A DIFFERENCE Katrina Boldry President, Owner & Designer Bold Lead Designs, LLC Aurora, Colorado BoldLeadDesigns.com kboldry@boldleaddesigns.com
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationIt s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP
It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings Emily Heil, PharmD, BCPS-AQ ID, AAHIVP Conflict of Interest I have no conflicts of interest to disclose related to the content
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationAntimicrobial Resistance Update for Community Health Services
Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationAntibiotics: Take a Time Out
Antibiotics: Take a Time Out Christine LaRocca, MD Telligen April 27, 2018 This material was prepared by Telligen, the Medicare Quality Innovation Network Quality Improvement Organization, under contract
More informationVisual and Instrumental Evaluation of Mottling and Striping
Visual and Instrumental Evaluation of Mottling and Striping Friedhelm Fensterseifer and Severin Wimmer BYK-Gardner User Meeting 2013 - Innsbruck, Austria Mottling / cloudiness of metallic coatings Irregular
More informationAntibiotic Stewardship Programs: The Secret of Getting Ahead is Getting Started. HRET HIIN Antimicrobial Stewardship June 1, 2017
Antibiotic Stewardship Programs: The Secret of Getting Ahead is Getting Started HRET HIIN Antimicrobial Stewardship June 1, 2017 1 Emily Koebnick, Program Manager, HRET WELCOME AND INTRODUCTIONS 2 Agenda
More informationWENDY WILLIAMS, MT(AMT) MSAH DIRECTOR LABORATORY AND PATHOLOGY SERVICES. Appalachian Regional Healthcare System apprhs.org
Incorporating Automation and Rapid Diagnostic Technologies into the Micro Lab's Lean Workflow to Boost Productivity, Shorten Length of Stay, and Improve Antibiotic Utilization WENDY WILLIAMS, MT(AMT) MSAH
More informationGeriatric Mental Health Partnership
Geriatric Mental Health Partnership September 8, 2017 First, let s test your knowledge about antibiotics http://www.cdc.gov/getsmart/community/about/quiz.html 2 Get Smart Antibiotics Quiz Antibiotics fight
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationPatterns of heredity can be predicted.
Page of 6 KEY CONCEPT Patterns of heredity can be predicted. BEFORE, you learned Genes are passed from parents to offspring Offspring inherit genes in predictable patterns NOW, you will learn How Punnett
More information17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France
Practical Issues for the clinical evaluation of QT/QTc interval prolongation 17 th Club Phase 1 Annual Meeting April 5, 2018 Pierre Maison-Blanche Hopital Bichat, Paris, France Disclosure Chiesi Pharmaceuticals
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationMHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative
MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!
More informationUnderstand the application of Antibiotic Stewardship regulations in LTC. Understand past barriers to antibiotic management concepts
Objectives Understand the application of Antibiotic Stewardship regulations in LTC Understand past barriers to antibiotic management concepts Understand benefits of adoption of antibiotic stewardship regulations
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationCase 2:14-cv KJM-KJN Document 2-5 Filed 02/03/14 Page 1 of 6 EXHIBIT E
Case 2:14-cv-00341-KJM-KJN Document 2-5 Filed 02/03/14 Page 1 of 6 EXHIBIT E Case 2:14-cv-00341-KJM-KJN Document 2-5 Filed 02/03/14 Page 2 of 6 1 EGG ECONOMICS UPDATE #338, Poultry Specialist (emeritus),
More information